What does “microdosing” mean in the GLP-1 context?
Standard semaglutide weight management protocols titrate from 0.25 mg weekly up toward 2.4 mg weeklyover a several-month period. “Microdosing” in clinical practice typically means starting lower (sometimes 0.1 mg weekly) and advancing more slowly, or maintaining at a dose below the standard protocol ceiling when that lower dose achieves the clinical goal.
The strategy is not FDA-defined or standardized across prescribers. It emerged from clinical practice as clinicians observed that many patients — particularly those starting GLP-1 therapy for the first time, those sensitive to GI effects, or those with more modest weight management goals — reached their effective dose at a fraction of the maximum approved amount.
Compounded semaglutide makes this possible in a way that branded pens like Ozempic and Wegovy do not. Branded devices have fixed dose steps. Compounded semaglutide — prepared by licensed 503A compounding pharmacies using pharmaceutical-grade semaglutide base — can be prepared in custom concentrations that allow fine-grained dose adjustments. PepScribe’s compounded semaglutide is prepared in the USA by licensed 503A pharmacies with no hidden overseas supply chain.
What does a representative microdosing semaglutide chart look like?
The following is illustrative of how clinicians structure low-dose semaglutide protocols — not a prescription, not personalized medical advice, and not a substitute for a clinician evaluation. Actual starting dose, step size, and ceiling are determined individually.
| Weeks | Typical dose range | Clinical focus |
|---|---|---|
| 1–4 | 0.1–0.25 mg/week | Tolerance assessment, GI adaptation |
| 5–8 | 0.25–0.5 mg/week | Appetite modulation onset |
| 9–12 | 0.5 mg/week (hold or advance) | Evaluate response; advance only if needed |
| 13+ | Individualized | Maintenance at effective dose |
The key principle: dose is titrated to the minimum effective amount for the individual patient’s goal, not automatically driven to the ceiling. Many patients find their maintenance dose is significantly below 1 mg weekly. Others need higher doses for adequate effect. The right dose is determined by clinical response, not by the table above.
The goal of a low-dose protocol is the lowest dose that modulates appetite — not the highest dose you can tolerate.
Why do some clinicians favor a low-dose semaglutide approach?
GLP-1 agonists reduce appetite and slow gastric emptying. Both effects are dose-dependent, but so is the nausea, vomiting, and GI discomfort that causes many patients to discontinue therapy. Clinical evidence from the STEP trial program — which tested semaglutide 2.4 mg for weight management — shows dose-dependent GI adverse events.
Starting low and advancing slowly is the standard recommendation in prescribing guidance for exactly this reason. “Microdosing” extends this logic by also questioning whether the maximum approved dose is necessary for every patient. Some patients achieve clinically meaningful appetite regulation at 0.25–0.5 mg weekly. If that dose is also the dose they tolerate without significant GI disruption, there’s a reasonable argument for staying there rather than continuing to titrate upward.
This is a clinical judgment that accounts for the patient’s specific weight management goal, their baseline GI sensitivity, their other medications, and their tolerance experience at each dose step. It’s not a one-size approach, and it’s not appropriate to self-titrate based on an online chart.
What is semaglutide — and what isn’t it?
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone that signals satiety to the brain, slows gastric emptying, and modulates glucose metabolism. It is used for weight management in adults.
Compounded semaglutide is a preparation made by a licensed 503A pharmacy from pharmaceutical-grade semaglutide base. It is not FDA-approved — no compounded drug product is. It is not the same as Ozempic or Wegovy, which are FDA-approved branded products with a specific formulation, device, and approval for labeled indications. Compounded semaglutide is a separate preparation; any comparison to branded products in terms of “same active ingredient” or “equivalent to Ozempic” would be misleading and clinicians don’t frame it that way.
Who is — and isn’t — a candidate?
GLP-1 agonist therapy — at any dose — requires a clinical evaluation that screens for contraindications. These include:
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- History of pancreatitis
- Severe renal impairment or end-stage renal disease
- Active eating disorder
- Pregnancy or planning pregnancy
A clinician also considers current medications for interactions (particularly other glucose-lowering agents in diabetic patients), and evaluates whether the weight management goal is appropriate for GLP-1 monotherapy, combination therapy, or a different approach entirely.
Frequently asked questions
What is microdosing semaglutide?
Microdosing refers to using semaglutide at doses below the standard weight management titration schedule — often 0.1 mg to 0.25 mg weekly rather than the 1 mg or 2.4 mg ceiling doses used in branded products. The rationale is to capture appetite regulation and metabolic benefits while minimizing GI side effects. This is an off-label approach managed by a prescribing clinician.
What does a microdosing semaglutide chart look like?
A typical low-dose titration chart starts at 0.1–0.25 mg weekly for 4–8 weeks, then steps up in small increments (0.1–0.25 mg) every 4 weeks based on tolerance and response. Maximum dose is individualized — many patients find their effective maintenance dose well below the ceiling doses used in branded products. Exact numbers must be set by your prescribing clinician, not pulled from online charts.
Is microdosing semaglutide effective for weight management?
Some patients achieve meaningful appetite suppression at sub-standard doses. Others require higher doses for adequate effect. There is no large controlled trial specifically on microdosing — the data comes from the broader semaglutide literature and clinical observation. Response is highly individual.
Does microdosing reduce semaglutide side effects?
Lower doses are associated with lower rates of nausea, vomiting, and GI distress in the dose-finding literature. However, individual variation is substantial. Some patients tolerate standard titration without issue; others benefit from a slower ramp. Microdosing is not a guaranteed side-effect elimination strategy.
Can I self-prescribe a microdosing semaglutide protocol?
No. Compounded semaglutide requires a prescription from a licensed clinician. The clinician also monitors for contraindications (personal or family history of thyroid cancer or MEN2, pancreatitis history, renal function), adjusts dosing based on response, and evaluates whether a GLP-1 agonist is appropriate for your specific health profile.
What is compounded semaglutide and how does it differ from Ozempic or Wegovy?
Compounded semaglutide is a separate preparation made by licensed 503A compounding pharmacies using pharmaceutical-grade semaglutide base. It is not the same product as Ozempic or Wegovy, which are FDA-approved branded drugs. Compounded semaglutide allows for dose flexibility that branded devices do not provide. It is not FDA-approved and is not a biosimilar.